Effects of short-term dexamethasone treatment on collagen synthesis and degradation markers in preterm infants with developing lung disease

Acta Paediatrica, International Journal of Paediatrics

Volumn 92, Issue 5, 2003, Pages 588-594

  Saarela, T ^a   Risteli, J ^a   Koivisto, M ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Collagen degradation; Collagen synthesis; Dexamethasone; Preterm infants

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; DEXAMETHASONE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 1 CARBOXYTELOPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CHILD CARE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INFANT; LUNG DISEASE; MALE; PATIENT MONITORING; PREMATURITY; PRIORITY JOURNAL; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; STEROID THERAPY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CHILD DEVELOPMENT; COLLAGEN; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GROWTH DISORDERS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LONGITUDINAL STUDIES; LUNG DISEASES; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0042922723     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035320310002687     Document Type: Article

References (29)

1. Halliday HL, Ehrenkrantz RA. Moderately early (4-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2000: CD001144
2. Halliday HL, Ehrenkrantz RA. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2000: CD001145
3. Halliday HL, Ehrenkrantz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2000: CD001146
4. Hymans JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113: 249-54
5. Gibson AT, Pearse RG, Wales JKH. Growth retardation after dexamethasone administration: assessment by knemometry. Arch Dis Child 1993; 69: 505-9
6. Weiler HA, Paes B, Shah JK, Atkinson SA. Longitudinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone. Early Hum Dev 1997; 47: 271-86
7. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998: 101http://www.pediatrics.org/cgi/content/full/101/5/e7
8. Shrivastava A, Lyon A, McIntosh N. The effect of dexamethasone on growth, mineral balance and bone mineralisation in preterm infants with chronic lung disease. Eur J Pediatr 2000; 159: 380-384
9. Risteli J, Risteli L. Products of bone collagen metabolism. In: Seibel MJ, Robins SP, Bilezikin JP, editors. Dynamics of bone and cartilage metabolism: principles and clinical applications. London Academic Press; 1999: 275-87
10. Crofton PM, Shrivastava A, Wade JC, Stephen R, Kelnar CJH, McIntoch N, Lyon AJ. Effects of dexamethasone treatment on bone and collagen turnover in preterm infants with chronic lung disease. Pediatr Res 2000; 48: 155-62
11. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-terminal propeptide of human type I collagen. Clin Chem 1996; 42: 947-54
12. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-40
13. Risteli J, Niemi S, Triveldi P, Mäentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmuno-assay for the aminoterminal propeptide of human type III procollagen. Clin Chem 1988; 34: 715-8
14. Vanhaesebrouck P, Kint J, van Kets H, Covaert P, Smets K, Defoort P, Leroy J. Aminoterminal propeptide of type III procollagen in cord blood and amniotic fluid of high-risk pregnancies: a biochemical approach to the dynamic assessment of deviant fetal growth. Pediatr Res 1994; 36: 71-6
15. Saarela T, Risteli J, Kauppila A, Koivisto M. Type I collagen markers in cord serum of appropriate vs small for gestational age infants born during the second half of pregnancy. Eur J Clin Invest 2001; 31: 438-43
16. Risteli L, Risteli J. Collagen metabolites in body fluids. In: Royce PM, Steinman B, editors. Connective tissue and its heritable disorders. New York: Wiley-Liss; 2002: in press
17. 2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994; 179: 405-17
18. Sassi M-L, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000; 26: 367-73
19. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127-32
20. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation; relation to calcium kinetics. Bone Miner 1994; 24: 81-94
21. Seibold-Weiger K, Wollmann HA, Ranke MB, Speer CP. Plasma concentrations of the carboxyterminal propeptide of type I procollagen (PICP) in preterm neonates form birth to term. Pediatr Res 2000; 48: 104-8
22. Crofton PM, Shrivastava A, Wade JC, Stephen R, Kelnar CJH, Lyon AJ, McIntoch N. Bone and collagen markers in preterm infants: relationship with growth and bone mineral content over the first 10 weeks of life. Pediatr Res 1999; 46: 581-7
23. Finer NN, Craft A, Vaucher YE, Clark RH, Sola A. Postnatal steroids: short-term gain, long-term pain? J Pediatr 2000; 137: 9-13
24. Hansen M, Stoltenberg M, Host NB, Lorenzen L, Bentsen KD. Glucocorticoids inhibit the synthesis of type III collagen, but do not affect the hepatic clearance of its aminoterminal propeptide (PIIINP). Scand J Clin Lab Invest 1995; 55: 543-8
25. Peretz A, Moris M, Willems D, Bergmann P. Is alkaline phosphatase an adequate marker of bone metabolism during acute corticosteroid treatment? Clin Chem 1996; 42: 102-3
26. NIH Consensus Conference. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995; 273: 413-8
27. Koob TJ, Jeffery JJ, Eisen AZ, Bauer EA. Hormonal interactions in mammalian collagenase regulation. Comparative studies in human and rat uterus. Biochim Biophys Acta 1980; 629: 13-23
28. Cockayne D, Cutroneo KR. Corticosteroid coordinate regulation of type I procollagen gene expression and procollagen DNA-binding proteins in chick skin fibroblasts. Biochemistry 1988; 27: 2736-45
29. Wilson DC, Cairns P, Halliday H, Reid M, McClure G, Dodge J. Randomised controlled trial of an aggressive nutritional regimen in sick very-low-birth-weight infants. Arch Dis Child 1997; 77: F4-11